Key facts
- Manuals
- 1
- Languages
- ZH
- Last added
- 2023-11-17
Featured Jiangsu Hengrui manuals

Jiangsu Hengrui Herombopag Olamine Tablets Technical Review Report (CXHS2000014-15)
This document is a technical review report for the marketing authorization of Herombopag Olamine Tablets (海曲泊帕乙醇胺片) by Jiangsu Hengrui Medicine Co., Ltd. The drug is a small molecule TPO-R agonist intended for the treatment of adult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy. The review was conducted by the Center for Drug Evaluation of China's National Medical Products Administration.
The report covers basic information about the applicant and drug, verification and compliance evaluation, and comprehensive review opinions on pharmacology, clinical pharmacology, efficacy, safety, and risk-benefit assessment. The application received conditional approval and priority review status, with final processing opinions including technical conclusions and post-marketing requirements. This manual is written in Chinese.
Covers: Basic Information · Verification and Compliance Evaluation · Indication · Pharmacological Evaluation · Clinical Pharmacology Evaluation · Efficacy Evaluation
Latest Jiangsu Hengrui manuals
Jiangsu Hengrui Herombopag Olamine Tablets Technical Review Report (CXHS2000014-15)
Other 22 pages · 978 KB · ZHTechnical review report by China's NMPA for Jiangsu Hengrui's Herombopag Olamine Tablets application for marketing authorization for severe aplastic anemia.
Questions answered in Jiangsu Hengrui manuals
What is the indication of Herombopag Olamine Tablets?
It is indicated for adult patients with severe aplastic anemia (SAA) who have failed immunosuppressive therapy (IST).
From: Jiangsu Hengrui Herombopag Olamine Tablets Technical Review Report (CXHS2000014-15)
What are the available specifications of Herombopag Olamine Tablets?
The tablets are available in 2.5 mg, 3.75 mg, and 5 mg strengths (calculated as C25H22N4O5).
From: Jiangsu Hengrui Herombopag Olamine Tablets Technical Review Report (CXHS2000014-15)
